Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Furosemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 7/20 | 0.83 |
| ▸ | CA12 | O43570 | 3/20 | 0.83 |
| ▸ | CA1 | P00915 | 3/20 | 0.83 |
| ▸ | CA2 | P00918 | 3/20 | 0.83 |
| ▸ | CA6 | P23280 | 3/20 | 0.83 |
| ▸ | CA7 | P43166 | 3/20 | 0.83 |
| ▸ | CA9 | Q16790 | 3/20 | 0.83 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.83 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.83 |
| ▸ | CA5A | P35218 | 2/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.83 |
| ▸ | CA4 | P22748 | 1/20 | 0.83 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.83 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.83 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.83 |
| ▸ | APP | P05067 | 9/20 | 0.65 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.61 |
| ▸ | AQP1 | P29972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furosemide SCHEMBL232189 | 1.00 | CISD1 (0.83) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL229185 | 0.92 | CISD1 (0.86) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL229240 | 0.92 | CISD1 (0.86) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL231246 | 0.91 | CISD1 (0.88) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL230594 | 0.91 | CISD1 (0.88) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL9811 | 0.91 | CISD1 (1.00) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL428921 | 0.91 | CISD1 (1.00) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL29406913 | 0.91 | CISD1 (1.00) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL2519788 | 0.90 | CISD1 (0.98) | CISD1CA12CA1CA2CA6 | |
| Furosemide SCHEMBL1109955 | 0.90 | CISD1 (0.98) | CISD1CA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | claimed |
| EP-2790686-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Auris Medical AG (CH) | 2014-10-22 | — | — | EP | claimed |
| WO-2013087090-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | AURIS MEDICAL AG (CH) | 2013-06-20 | — | — | WO | claimed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | claimed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | claimed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | claimed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | claimed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | disclosed |
| EP-2790686-B1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Zilentin AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | OTOLANUM AG (CH) | 2020-07-14 | — | — | US | disclosed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | CISD1 2281/4885CA12 1656/4885CA1 559/4885 |
| US-20240009153-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CISD1 3650/4885CA12 1338/4885CA1 988/4885 |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A13, SLC6A11 | CISD1 1573/4885CA12 1181/4885CA1 1024/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | CISD1 2281/4885CA12 1656/4885CA1 559/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | CISD1 3132/4885CA12 1302/4885CA1 847/4885 |
| US-10709682-B2 | Treatment of tinnitus through modulation of chloride co-transporter NKCC1 in the auditory system | SLC6A1, SLC6A11, SLC6A13 | CISD1 1493/4885CA12 1270/4885CA1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.